Medical condition
Sickle Cell Disease
Sickle Cell Disease is a medical condition tracked by NovaPharmaNews across 4 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- exagamglogene autotemcel (CASGEVY) Blood and blood forming organs (B06)
- voxelotor (OXBRYTA) Blood and blood forming organs (B06)
- crizanlizumab (ADAKVEO) Blood and blood forming organs (B06)
- hydroxycarbamide (HYDREA) Antineoplastic and immunomodulating agents (L01)
Latest Sickle Cell Disease news
FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.
FDA Approves First CRISPR Gene Therapy for Sickle Cell Disease
The FDA has approved Zynteglo, the first CRISPR gene therapy for sickle cell disease, offering new hope for patients with this debilitating condition.